Phagenesis Ltd
Conor Mulrooney has a diverse work experience in the medical device and diagnostic industry. Conor co-founded and served as the COO of Phagenesis Limited, overseeing the development and production of innovative medical devices for dysphagia treatment. At UMIP, Conor worked as a Business Manager, managing various medical device and diagnostic product development programs. Conor was also involved in the creation of new spin-out businesses and secured multiple IP license deals. In their role as the Systems Development Manager at Tepnel Life Sciences plc, Conor led a multidisciplinary team in the development of robotic systems for DNA purification and was responsible for the sale and validation of the integrated systems. Prior to that, they worked as a Development Scientist, contributing to the organization's research efforts.
Conor Mulrooney attended Ulster University from 1989 to 1996. No specific degree or field of study was mentioned.
This person is not in any offices
Phagenesis Ltd
1 followers
Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.